Profile picture

Doctor Chao Gao

First Affiliated Hospital of University of Science and Technology of China, Hefei (China)
Membership: FESC Member
Follow
Biography
Chao Gao M.D., Ph.D. serves as Director of the Department of Cardiology, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital). He was trained at Air Force Medical University of China, Radboud University of the Netherlands, and the National University of Ireland Galway. His primary interests focus on translational basic research of CAD/clinical trials of CAD and structural heart disease. He leads the REC study group and has published more than 100 articles in journals such as The Lancet, BMJ, European Heart Journal, JACC, and Cell Metabolism.
Logo ESC

Contributor content

Impact of stepwise dual antiplatelet therapy de-escalation according to body mass index in patients undergoing drug-coated balloon angioplasty: insights from the REC-CAGEFREE II trial
Presentation
Impact of stepwise dual antiplatelet therapy de-escalation according to body mass index in patients undergoing drug-coated balloon angioplasty: insights from the REC-CAGEFREE II trial
Impact of established cardiovascular disease on treatment effect of stepwise versus standard dual antiplatelet in patients treated with drug-coated balloon: insights from the REC-CAGEFREE II trial
Presentation
Impact of established cardiovascular disease on treatment effect of stepwise versus standard dual antiplatelet in patients treated with drug-coated balloon: insights from the REC-CAGEFREE II trial
Impact of stepwise dual antiplatelet therapy de-escalation in patients with proximal LAD disease undergoing drug-coated balloon angioplasty: insights from the REC-CAGEFREE II trial
Presentation
Impact of stepwise dual antiplatelet therapy de-escalation in patients with proximal LAD disease undergoing drug-coated balloon angioplasty: insights from the REC-CAGEFREE II trial
Efficacy and safety of drug-coated balloon angioplasty in patients with acute coronary syndromes: insights from the REC-CAGEFREE I trial
Presentation
Efficacy and safety of drug-coated balloon angioplasty in patients with acute coronary syndromes: insights from the REC-CAGEFREE I trial
Antiplatelet regimen in patients with drug-coated balloons for coronary in-stent restenosis: insights from the REC-CAGEFREE II trial
Presentation
Antiplatelet regimen in patients with drug-coated balloons for coronary in-stent restenosis: insights from the REC-CAGEFREE II trial
Impact of diabetes mellitus on clinical outcomes of stepwise dual antiplatelet therapy de-escalation after drug-coated balloon angioplasty: insights from the REC-CAGEFREE II trial
Presentation
Impact of diabetes mellitus on clinical outcomes of stepwise dual antiplatelet therapy de-escalation after drug-coated balloon angioplasty: insights from the REC-CAGEFREE II trial
Impact of stepwise dual antiplatelet therapy de-escalation in patients with high bleeding risk undergoing drug-coated balloon angioplasty: Insights from the REC-CAGEFREE II trial
Presentation
Impact of stepwise dual antiplatelet therapy de-escalation in patients with high bleeding risk undergoing drug-coated balloon angioplasty: Insights from the REC-CAGEFREE II trial
One-year clinical outcomes and the impact of procedural configurations in patients with left atrial appendage occlusion
Presentation
One-year clinical outcomes and the impact of procedural configurations in patients with left atrial appendage occlusion
Treatment of complex coronary artery disease in patients with diabetes mellitus and chronic kidney disease: 10-year results comparing outcomes of CABG and PCI in the SYNTAXES trial
Presentation
Treatment of complex coronary artery disease in patients with diabetes mellitus and chronic kidney disease: 10-year results comparing outcomes of CABG and PCI in the SYNTAXES trial
A prospective multicentre randomized all-comers trial to assess the safety and effectiveness of the ultra-thin-strut sirolimus-eluting coronary stent Supraflex: 2-year results of the TALENT trial
Presentation
A prospective multicentre randomized all-comers trial to assess the safety and effectiveness of the ultra-thin-strut sirolimus-eluting coronary stent Supraflex: 2-year results of the TALENT trial